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Epithelial-Mesenchymal Transition (EMT) is a
biological program that induces epithelial cells to
morph into a mesenchymal stem cell-like phenotype.2
Recently our lab identified that cell division is critical
for the gain of stem cell properties during EMT but not
for mesenchymal properties. Epigenetic programming
is critical for both cell division and EMT regulation.
Epigenetic regulators include various histone or
chromatin remodeling proteins such as EZH2, HDACs,
and DNMTs.
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Figure 4: A) Dose response curve of cell viability upon drug
treatment in MCF10A + 6 days TGF-β1, with calculated IC50 and
IC25. B) Dose response curve of cell viability upon drug treatment in
SUM159, with calculated IC50 and IC25. 6

Mesenchymal Properties
Figure 1: Basics of EMT (Epithelial to Mesenchymal Transition.
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Figure 3: A) Western blot showing time course of TGF-β1 induction of EMT in
MCF10A cells, leading to acquisition of mesenchymal properties by the normally
epithelial cell line. B) The mammosphere data demonstrated acquisition of stemness
properties upon TGF-β1 induction of EMT in MCF10A cells. C) MCF10A cell lines
were exposed to TGF-β1 for 6 days in which they exhibited mesenchymal markers.
This was not changed upon cell division inhibition. D) Upon cell division inhibition in
MCF10A treated with 6 days of TGF-β1, stemness properties were inhibited. Cell

division inhibition leads to no change in mesenchymal properties, but
is capable of inhibiting stemness acquisition in MCF10A cells1.

Methods
● EMT-enriched cell line: SUM159 cell line
● Epithelial cell line: MCF10A. EMT was induced
Figure 2: A) EZH2 (Enhancer of Zeste Homolog 2) is an enzyme that participates
in histone methylation. Inhibition of EZH2 by Tazemetostat results in a prevention
of histone methylation.5 B) HDACs (Histone Deacetylases) are a class of
enzymes that catalyze the removal of acetyl groups from histone proteins.
Inhibition of HDACs by the drug Vorinostat results in a persistence of acetylation of
histone proteins.3 C) DNMTs (DNA methyltransferases) are a class of enzymes
that catalyze the transfer of methyl groups to DNA. Decitabine is a DNMT inhibitor
which ultimately prevents the methylation of DNA. 4

●
●
●
●

using TGF-β1 for 6 days.
Inhibitors Tazemetostat, Vorinostat, and Decitabine
were utilized on cells.
IC50 was determined using IncuCyte
Protein analysis by Western Blot
Stemness analysis by Mammosphere assay
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Due to the link of epigenetic regulation in both EMT
and cell division, we hypothesize that a particular
class of epigenetic inhibitors will be able to unlink the
gain of mesenchymal and stemness properties.

Figure 5: Western blot analysis of drug treated MCF10A and
SUM159. Decitabine provided conflicting results, with more studies
required. Vorinostat was capable of inhibiting mesenchymal
properties and Tazemetostat has no effect on mesenchymal
properties acquisition. 6
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Figure 7: A) Figure depicts the EMT process. Epithelial cells convert to
Mesenchymal-like cells with acquisition of stem cell like properties. B) When
cell division is inhibited in the EMT process what results are cells that
possess mesenchymal properties but not stem cell like properties. C)
The addition of Decitabine concluded that further study will be needed to
determine its effect on mesenchymal properties, but it is capable of inhibiting
the acquisition of stem cell like properties. D) The addition of Vorinostat
concluded that the drug indeed inhibits the acquisition of mesenchymal
properties as well as the inheritance of stem cell like properties. E) The
addition of Tazemetostat concluded that the drug has no real effect on
mesenchymal properties, but capable of inhibiting acquisition of stemness
properties. This drug’s results proved to be most similar to the effect of
inhibiting cell division during EMT. 6
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Figure 6: Mammosphere assay was conducted on drug treatment
cell lines for period of 7 days. Results indicate that Decitabine
prevents MCF10A cells from the gain of stemness properties, but is
not able to revert the gain of stemness properties already found in
SUM159. Vorinostat and Tazemetostat are capable of inhibiting
stemness properties in both cell lines. 6
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